Rheumatic Immune-Related Adverse Events With Anti-cyclic Citrullinated Peptide Positivity and Cutaneous Adverse Drug Reactions: A Case Report

We report the case of a patient who experienced rheumatic immune-related adverse events (irAEs) with anti-cyclic citrullinated peptide (anti-CCP) positivity and cutaneous adverse drug reactions. A 59-year-old woman with malignant melanoma who was treated with nivolumab as postoperative adjuvant therapy developed polyarthralgia with anti-CCP positivity and dermatologic adverse events caused by celecoxib or lansoprazole. Her rheumatic and cutaneous symptoms greatly improved with oral glucocorticoid treatment. The findings of this case suggest that after treatment with immune checkpoint inhibitors, it is necessary to pay attention to irAEs and provide appropriate treatment.